Given evidence implicating Bin1 elevation in phosphorylated tau accumulation and neurofibrillary tangle pathology in AD, we explored whether administration of the Bin1 mAb 99D that produced a preclinical therapeutic benefit in IBD could produce any parallel benefits in model of tauopathy/AD. This evidence concerns the gene MAPT and inflammatory bowel disease.